company background image
NOVOB logo

Novo Nordisk BRSE:NOVOB Stock Report

Last Price

CHF86.71

Market Cap

CHF388.3b

7D

0%

1Y

45.7%

Updated

06 Dec, 2023

Data

Company Financials +

NOVOB Stock Overview

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.

NOVOB fundamental analysis
Snowflake Score
Valuation1/6
Future Growth3/6
Past Performance6/6
Financial Health4/6
Dividends0/6

Novo Nordisk A/S Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Novo Nordisk
Historical stock prices
Current Share Pricekr.86.71
52 Week Highkr.87.51
52 Week Lowkr.59.42
Beta0.19
1 Month Change0%
3 Month Change-0.92%
1 Year Change45.72%
3 Year Change175.26%
5 Year Change278.02%
Change since IPO74.29%

Recent News & Updates

Recent updates

Shareholder Returns

NOVOBCH PharmaceuticalsCH Market
7D0%-0.1%0.8%
1Y45.7%-4.5%3.3%

Return vs Industry: NOVOB exceeded the Swiss Pharmaceuticals industry which returned -9.5% over the past year.

Return vs Market: NOVOB exceeded the Swiss Market which returned -0.9% over the past year.

Price Volatility

Is NOVOB's price volatile compared to industry and market?
NOVOB volatility
NOVOB Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement3.1%
Market Average Movement3.4%
10% most volatile stocks in CH Market7.7%
10% least volatile stocks in CH Market1.8%

Stable Share Price: NOVOB has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine NOVOB's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
192361,412Lars Jorgensenhttps://www.novonordisk.com

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases.

Novo Nordisk A/S Fundamentals Summary

How do Novo Nordisk's earnings and revenue compare to its market cap?
NOVOB fundamental statistics
Market capCHF388.31b
Earnings (TTM)CHF9.54b
Revenue (TTM)CHF27.18b

40.7x

P/E Ratio

14.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NOVOB income statement (TTM)
Revenuekr.214.49b
Cost of Revenuekr.34.01b
Gross Profitkr.180.48b
Other Expenseskr.105.17b
Earningskr.75.31b

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Jan 31, 2024

Earnings per share (EPS)16.89
Gross Margin84.14%
Net Profit Margin35.11%
Debt/Equity Ratio28.5%

How did NOVOB perform over the long term?

See historical performance and comparison

Dividends

1.0%

Current Dividend Yield

42%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.